Want to see DRUG full AI Analyst Report?
DRUG Stock Chart & Stats
$79.49
$2.29(3.21%)
At close: 4:00 PM EDT
$79.49
$2.29(3.21%)
Day’s Range― - ―
52-Week Range$38.23 - $123.75
Previous Close$40.4
Volume103.68K
Average Volume (3M)167.39K
Market Cap
$698.77M
Enterprise Value$473.17
Total Cash (Recent Filing)$308.33M
Total Debt (Recent Filing)$65.70K
Price to Earnings (P/E)―
Beta5.60
Next Earnings
Dec 17, 2026EPS Estimate
-1.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.76
Shares Outstanding9,864,061
10 Day Avg. Volume109,387
30 Day Avg. Volume167,394
Financial Highlights & Ratios
PEG Ratio-0.27
Price to Book (P/B)7.08
Price to Sales (P/S)0.00
P/FCF Ratio-66.82
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$145.00Price Target Upside82.41% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-3.52
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage And Funding FlexibilityMinimal debt reduces refinancing pressure and preserves financial flexibility while the larger equity base provides a stronger capital cushion. This structure can help Bright Minds fund clinical development without immediate dependence on debt markets.
Proprietary Neuropsychiatric PipelineA focused pipeline of proprietary serotonin-targeting compounds gives Bright Minds potential differentiation across several neurological indications. Successful development could support partnering, licensing, milestones or future royalties beyond a single product opportunity.
Cross-Border Disclosure And GovernanceMaintaining structured governance and cross-border reporting supports transparency with shareholders and helps preserve access to international capital. These practices are important for a clinical biotech that relies on financing while advancing long-duration drug programs.
Bears Say
No Commercial RevenueThe absence of recurring product revenue leaves Bright Minds without an operating income base to fund research, trials and overhead. Until a candidate is approved or partnered, progress remains dependent on external financing or contingent transaction income.
Widening Net LossesLosses have expanded materially as the company invests in development without commercial revenue. Persistent negative operating results increase the amount of capital required to reach milestones and raise the risk of further equity issuance or program prioritization.
Accelerating Cash BurnThe sharp increase in operating cash burn indicates rising spending intensity and a shortening window before additional funding may be needed. Even with low debt, sustained negative free cash flow can constrain trial execution and increase financing dependence.
Bright Minds Biosciences News
DRUG FAQ
What was Bright Minds Biosciences’s price range in the past 12 months?
Bright Minds Biosciences lowest stock price was $38.23 and its highest was $123.75 in the past 12 months.
What is Bright Minds Biosciences’s market cap?
Bright Minds Biosciences’s market cap is $698.77M.
When is Bright Minds Biosciences’s upcoming earnings report date?
Bright Minds Biosciences’s upcoming earnings report date is Dec 17, 2026 which is in 105 days.
How were Bright Minds Biosciences’s earnings last quarter?
Bright Minds Biosciences released its earnings results on Aug 14, 2026. The company reported -$0.173 earnings per share for the quarter, beating the consensus estimate of -$1.223 by $1.05.
Is Bright Minds Biosciences overvalued?
According to Wall Street analysts Bright Minds Biosciences’s price is currently Undervalued.
Does Bright Minds Biosciences pay dividends?
Bright Minds Biosciences does not currently pay dividends.
What is Bright Minds Biosciences’s EPS estimate?
Bright Minds Biosciences’s EPS estimate is -1.06.
How many shares outstanding does Bright Minds Biosciences have?
Bright Minds Biosciences has 9,864,061 shares outstanding.
What happened to Bright Minds Biosciences’s price movement after its last earnings report?
Bright Minds Biosciences reported an EPS of -$0.173 in its last earnings report, beating expectations of -$1.223. Following the earnings report the stock price went up 3.977%.
Which hedge fund is a major shareholder of Bright Minds Biosciences?
Currently, no hedge funds are holding shares in DRUG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bright Minds Biosciences
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company’s BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.
DRUG Stock 12 Month Forecast
Average Price Target
$145.00
▲(82.41% Upside)
Technical Analysis
Ownership Overview
20.92% Insiders
4.37% Mutual Funds
52.81% Other Institutional Investors
16.97% Public Companies and
Individual Investors